Qiagen NV (QGEN)

28.73
0.05 0.17
NASDAQ : Services
Prev Close 28.68
Open 28.64
Day Low/High 28.51 / 28.68
52 Wk Low/High 19.94 / 28.53
Volume 85.71K
Avg Volume 820.70K
Exchange NASDAQ
Shares Outstanding 225.88M
Market Cap 6.48B
EPS 0.30
Div & Yield N.A. (N.A)

Latest News

QIAGEN's QuantiFERON-TB Test Wins Tender For Testing Of Republic Of Korea Armed Forces Recruits

QIAGEN's QuantiFERON-TB Test Wins Tender For Testing Of Republic Of Korea Armed Forces Recruits

Selected for screening of 340,000 recruits in 2017 as part of national TB control strategy

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

Adjustment of conversion ratio under 0.375% Senior Unsecured Convertible Notes due 2019 due to reduction in number of shares outstanding and direct capital repayment to shareholders

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

QIAGEN Announces Adjustment Of Conversion Ratio Under Its 0.375% Senior Unsecured Convertible Notes Due 2019 (ISIN XS1046477235)

Adjustment of conversion ratio under 0.375% Senior Unsecured Convertible Notes due 2019 due to reduction in number of shares outstanding and direct capital repayment to shareholders

QIAGEN Announces Details For Completion Of Approximately $250 Million Synthetic Share Repurchase

QIAGEN Announces Details For Completion Of Approximately $250 Million Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment set for completion in January 2017

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

Powerful multi-omics data management solution and highly curated 'omics' data sets complement QIAGEN's industry-leading interpretation solutions

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

Launch of new QIAact gene panels and customized panels service complemented by performance upgrades that further differentiate first Sample to Insight NGS sequencing solution

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

U.S. submission builds on 2016 launch of fourth-generation test in more than 60 countries and already used in more than 600,000 people to date

QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines From U.S. Professional Societies

QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines From U.S. Professional Societies

New guidelines recommend broader use of modern blood TB tests like QuantiFERON-TB Gold over the 100-year-old tuberculin skin test

QIAGEN's GeneReader NGS System Streamlines Data Management For Labs

QIAGEN's GeneReader NGS System Streamlines Data Management For Labs

New middleware co-developed with Genohm ensures full chain of custody from Sample to Insight and integrates with most LIMS systems

QIAGEN GeneReader NGS System To Relaunch In U.S. Market

QIAGEN GeneReader NGS System To Relaunch In U.S. Market

New improved chemistry for first Sample to Insight next-generation sequencing solution to be made available to first customers in December 2016

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment to shareholders expected to be completed in January 2017

QIAGEN Launches QIAscout For Single-cell Isolation

QIAGEN Launches QIAscout For Single-cell Isolation

Compact, versatile and yet very affordable instrument provides unique front-end in workflows for molecular analysis of individual cells

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.

QIAGEN Unveils Unique Sample To Insight Solutions For Liquid Biopsies And Hereditary Diseases

QIAGEN Unveils Unique Sample To Insight Solutions For Liquid Biopsies And Hereditary Diseases

All-in-One library prep kit, plus collection, stabilization and bioinformatics solutions enable NIPT and cancer research

QIAGEN Launches High-throughput Solutions For Human ID Databases

QIAGEN Launches High-throughput Solutions For Human ID Databases

Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting

QIAGEN Announces Plans To Return Approximately $250 Million To Shareholders Via Synthetic Share Repurchase Proposal

QIAGEN Announces Plans To Return Approximately $250 Million To Shareholders Via Synthetic Share Repurchase Proposal

Proposal would adjust capital structure through 4% reduction in number of shares outstanding and direct capital repayment to shareholders

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEUA, BPMC, CAA, CAT, COMM, DAIO, DKS, EFII, HDS, HOG, ISTR, KEM, MSCC, MT, NWHM, QGEN, QLYS, TPRE Downgrades: COHU, DMD, EMN, GRC, SFS, SYNA, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Diversified Services Stocks Nudging The Industry Higher

3 Diversified Services Stocks Nudging The Industry Higher

TheStreet highlights 3 stocks pushing the diversified services industry higher today.

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) stock is jumping on Friday morning after the company posted earnings and revenue that topped analysts’ projections for the 2016 second quarter.

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Trade-Ideas LLC identified Qiagen (QGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate